

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM728685

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
CMP PHARMA, INC.		05/12/2022	Corporation: NORTH CAROLINA
CMP ACQUISITION COMPANY LLC		05/12/2022	Limited Liability Company: DELAWARE
CMP DEVELOPMENT LLC		05/12/2022	Limited Liability Company: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	First Horizon Bank fka First Tennessee Bank National Association
<b>Street Address:</b>	211 Franklin Road
<b>Internal Address:</b>	Suite 300
<b>City:</b>	Brentwood
<b>State/Country:</b>	TENNESSEE
<b>Postal Code:</b>	37027
<b>Entity Type:</b>	banking corporation: TENNESSEE

## PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
<b>Registration Number:</b>	4028443	DERMACLOUD
<b>Registration Number:</b>	1288620	SPS
<b>Registration Number:</b>	1600274	ABSORBASE
<b>Registration Number:</b>	1377857	ORACIT
<b>Registration Number:</b>	4046667	TRIANEX
<b>Registration Number:</b>	5365294	CAROSPIR
<b>Serial Number:</b>	88741769	ATORVALIQ
<b>Serial Number:</b>	90126778	LIQPLAV
<b>Serial Number:</b>	90522858	LIQREV
<b>Serial Number:</b>	90522907	NORLIQVA
<b>Serial Number:</b>	90058609	TORVIQUID

## CORRESPONDENCE DATA

Fax Number: 6157426293

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent*

TRADEMARK

*using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 615-259-6126  
**Email:** trademarks@bassberry.com  
**Correspondent Name:** Marian Moore  
**Address Line 1:** 150 3rd Ave. S.  
**Address Line 2:** Suite 2800  
**Address Line 4:** Nashville, TENNESSEE 37201

<b>ATTORNEY DOCKET NUMBER:</b>	105528.0188
--------------------------------	-------------

<b>NAME OF SUBMITTER:</b>	Marian Moore
---------------------------	--------------

<b>SIGNATURE:</b>	/Marian Moore/
-------------------	----------------

<b>DATE SIGNED:</b>	05/18/2022
---------------------	------------

**Total Attachments: 8**

source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page1.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page2.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page3.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page4.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page5.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page6.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page7.tif  
source=First Horizon - CMP - 2022 - Amended and Restated IP Security Agreement#page8.tif

**AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**THIS AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT**, dated as of May 12, 2022 (as amended, supplemented or otherwise modified from time to time, the “Intellectual Property Security Agreement”), is made by the undersigned (the “Grantors”) in favor of First Horizon Bank, a Tennessee banking corporation formally known as First Tennessee Bank National Association, as administrative agent for itself and the Lenders (in such capacity, the “Administrative Agent”) under the Credit Agreement.

**RECITALS**

WHEREAS, pursuant to (i) that certain Amended and Restated Credit Agreement of even date herewith by and among CMP PHARMA, INC., a North Carolina corporation (the “Borrower”), CMP ACQUISITION COMPANY LLC, a Delaware limited liability company (“Parent Guarantor”), the banks and other financial institutions or entities (the “Lenders”) from time to time parties thereto and Administrative Agent (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), (ii) that certain Amended and Restated Guarantee and Collateral Agreement of even date herewith by and among Borrower, Parent Guarantor, and Administrative Agent (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”) and (iii) that certain Second Amended and Restated Guarantee and Collateral Agreement of even date herewith by and among CMP Development LLC, a Delaware limited liability company and Administrative Agent (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “CMP Development Guarantee and Collateral Agreement”); capitalized terms not otherwise defined herein and not otherwise noted parenthetically as being defined in other agreements shall have the meanings set forth in the Credit Agreement, the Lenders have agreed to make and continue to make certain extensions of credit to the Borrower under the Credit Agreement, all as more specifically described therein;

WHEREAS, it is a condition precedent to the obligation of the Lenders to make and continue to make their respective extensions of credit to the Borrower under the Credit Agreement that the Grantors execute and deliver this Intellectual Property Security Agreement to the Administrative Agent for recording with the United States Patent and Trademark Office and the United States Copyright Office; and

WHEREAS, the Grantors desire to execute this Intellectual Property Security Agreement to satisfy the condition described in the preceding paragraph.

**AGREEMENT**

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantors agree as follows:

SECTION 1. GRANT OF SECURITY. The Grantors hereby grant to the Administrative Agent, for the ratable benefit of the Lenders, a security interest in and to all of Grantors’ right, title and interest in and to the following (the “Intellectual Property Collateral”), as collateral security for the prompt

and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Grantors' Obligations (as defined in the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable):

(a) (1) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith (other than any "intent to use" trademark application for which a statement of use has not yet been filed (but only until such statement is filed with, and accepted by, the United States Patent and Trademark Office or the equivalent thereof in any jurisdiction)), including, without limitation, each trademark registration and application for trademark registration identified in Schedule 1, (2) the right to obtain all renewals thereof, (3) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations thereof, (4) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof), and (5) all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto, together in each case with the goodwill of the business connected with the use of, and symbolized by, each of the above (collectively, the "Trademarks");

(b) (1) all letters patent, all reissues and extensions thereof, including, without limitation, any of the foregoing identified in Schedule 2, (2) all applications for letters patent and all divisions, continuations and continuations-in-part thereof, including, without limitation, any of the foregoing identified in Schedule 2, (3) all rights to obtain any reissues or extensions of the foregoing, (4) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations thereof, and (5) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof) (collectively, the "Patents");

(c) (1) all copyrights, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof, and all applications in connection therewith, including, without limitation, all copyright registrations, and applications for copyright registrations identified in Schedule 3, (2) the right to obtain all renewals thereof, (3) the rights to print, publish and distribute any of the foregoing, (4) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations thereof, (5) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof), and (6) all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto (collectively, the "Copyrights");

(d) (1) all Patent Licenses, Trademark Licenses, and Copyright Licenses, as defined in the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable (except to the extent any such Patent License, Trademark License or Copyright License constitutes Excluded Intellectual Property, as defined in the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable, (2) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations of any of the foregoing, (3) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments

under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof), and (4) all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto;

(e) all right, title and interest of CMP Pharma, Inc. (“CMP”) in and to the Security Interest (defined below) pursuant to that certain Amended and Restated Intellectual Property Security Agreement dated December 1, 2017, whereby CMP Development LLC (“CMP Development”) has granted to CMP a continuing security interest in certain Intellectual Property Collateral (as defined therein), including, without limitation, the CAROSPIR trademark identified on Schedule 1 and the patents identified on Schedule 2 (the “Security Interest”); and

(f) any and all proceeds of the foregoing.

SECTION 2. RECORDATION. The Grantors authorize and request that the Register of Copyrights, the Commissioner of Patents and Trademarks and any other applicable government officer record this Intellectual Property Security Agreement.

SECTION 3. EXECUTION IN COUNTERPARTS. This Intellectual Property Security Agreement may be executed in any number of counterparts (including by telecopy), each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 4. GOVERNING LAW. Unless otherwise expressly set forth herein, this Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York (including Sections 5-1401 and 5-1402 of the General Obligations Law of the State of New York) without reference to the conflicts or choice of law principles thereof other than such Section 5-1401, except to the extent that the laws of a particular jurisdiction other than the State of New York govern the perfection, priority or enforcement of liens on and security interests in the Collateral.


SECTION 5. CONFLICT PROVISION. This Intellectual Property Security Agreement has been entered into in conjunction with the provisions of the Credit Agreement and the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable. The rights and remedies of each party hereto with respect to the security interest granted herein are without prejudice to, and are in addition to those set forth in the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable, and the Credit Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Intellectual Property Security Agreement are in conflict with the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable, or the Credit Agreement, the provisions of the Guarantee and Collateral Agreement or the CMP Development Guarantee and Collateral Agreement, as applicable, or the Credit Agreement shall govern.

SECTION 6. AMENDMENT AND RESTATEMENT. This Intellectual Property Security Agreement amends and restates that certain Intellectual Property Security Agreement dated December 1, 2017, executed by Grantors in favor of the Administrative Agent.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned Grantors have caused this Intellectual Property Security Agreement to be duly executed and delivered as of the date first above written.

CMP PHARMA, INC.

By:   
Name: Gerald Sakowski  
Title: Chief Executive Officer

CMP ACQUISITION COMPANY LLC

By: \_\_\_\_\_  
Name: George Aitken-Davies  
Title: President

CMP DEVELOPMENT LLC

By:   
Name: Gerald Sakowski  
Title: Chief Executive Officer

IN WITNESS WHEREOF, the undersigned Grantors have caused this Intellectual Property Security Agreement to be duly executed and delivered as of the date first above written.

CMP PHARMA, INC.

By: \_\_\_\_\_  
Name: Gerald Sakowski  
Title: Chief Executive Officer

CMP ACQUISITION COMPANY LLC

By:  \_\_\_\_\_  
Name: George Aitken-Davies  
Title: President

CMP DEVELOPMENT LLC

By: \_\_\_\_\_  
Name: Gerald Sakowski  
Title: Chief Executive Officer

**Schedule 1 to Amended and Restated Intellectual Property Security Agreement**

**REGISTERED TRADEMARKS AND TRADEMARK APPLICATIONS**

<b>Owner</b>	<b>Mark</b>	<b>Jurisdiction</b>	<b>Serial No. / Registration No.</b>	<b>Application/ Registration Date</b>
CMP Pharma, Inc.	DERMACLOUD	US	4,028,443	9/20/11
CMP Pharma, Inc.	SPS	US	1,288,620	8/7/84
CMP Pharma, Inc.	ABSORBASE	US	1,600,274	6/12/90
CMP Pharma, Inc.	ORACIT	US	1,377,857	1/14/86
CMP Pharma, Inc.	TRIANEX for pharmaceutical products, namely, topical corticosteroids	US	4,046,667	10/25/11
CMP Pharma, Inc.	ATORVALIQ	US	88/741,769	12/30/19
CMP Development LLC	CAROSPIR	US	5,365,294	10/8/14
CMP Development LLC	LIQPLAV	US	90/126,778	8/20/20
CMP Development LLC	LIQREV	US	90/522,858	2/10/21
CMP Development LLC	NORLIQVA	US	90/522,907	2/10/21
CMP Development LLC	TORVIQUID	US	90/058,609	7/17/20



**Schedule 2 to Amended and Restated Intellectual Property Security Agreement**

**REGISTERED PATENTS AND PATENT APPLICATIONS**

Owned by CMP Development LLC

<b>Title</b>	<b>Pat. No.</b>	<b>App. No.</b>	<b>Filing Date</b>	<b>Pat. No.</b>	<b>Issue Date</b>	<b>Pat. Expiry</b>	<b>Comments†</b>
Spironolactone aqueous formulations		15/337,559	10/28/16	9757394	09/12/17	10/28/36	CaroSpir® OB-listed
Spironolactone aqueous formulations		15/665,014	07/31/17	10493083	12/03/19	10/28/36	CaroSpir® OB-listed
Spironolactone aqueous formulations		16/682,477	11/13/19	10624906	04/21/20	10/28/36	CaroSpir® OB-listed
Spironolactone aqueous formulations		16/823,604	03/19/20	10660907	05/26/20	10/28/36	CaroSpir® OB-listed
Spironolactone aqueous formulations		16/878,092	05/19/20	10888570	01/12/21	10/28/36	CaroSpir® OB-listed
Spironolactone aqueous formulations		17/111,578	12/04/20	n/a	n/a	n/a	Pending
Spironolactone aqueous formulations		17/383,770	07/23/21	n/a	n/a	n/a	Pending and allowed
Spironolactone aqueous formulations		17/383,761	07/23/21	n/a	n/a	n/a	Pending and allowed
Potassium phosphates composition for injection		16/389,181	04/19/19	10632150	04/28/20	04/19/39	Potassium Phosphates OB-listed

† **Abbreviation:** "OB-listed" means U.S. patent is listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (aka the Orange Book) for identified product.

**Schedule 3 to Amended and Restated Intellectual Property Security Agreement**

**REGISTERED COPYRIGHTS AND COPYRIGHT APPLICATIONS**

<b>Full Title</b>	<b>Copyright Number</b>	<b>Date</b>
“Isoniazid syrup USP”	TX0002138317	8/3/87
“Oracit”	TX0002138363	8/3/87
“SPS suspension”	TX0001687393	2/27/85

32811546.3